A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT‑7117 in Subjects With Erythropoietic Protoporphyria
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2019
At a glance
- Drugs MT 7117 (Primary)
- Indications Erythropoietic protoporphyria
- Focus Therapeutic Use
- Acronyms ENDEAVOR
- Sponsors Mitsubishi Tanabe Pharma America
- 30 Jan 2019 Planned End Date changed from 1 Mar 2019 to 1 Dec 2019.
- 30 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Sep 2018.
- 10 Jul 2018 Status changed from not yet recruiting to recruiting.